As for clinical application, the presence of HER2 receptors on the surface of breast cancer cells provides a promising approach for utilizing HER2-targeted liposomes that facilitate direct delivery of the therapeutic agents to the cancer cells and enhance treatment efficacy. This evidence concerns the gene ERBB2 and breast carcinoma.